YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Perrigo (PRGO) shares soared 6.1% in the last trading session to close at $14.68. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 6.2% loss over the past four w…
On August 19, Merck (MRK) said its personalized cancer vaccine had proved effective in a large, late-stage melanoma study, and Wall Street responded fast. Merck shares closed up about 12.5% that day, one of the biggest single-day moves the…
Healthcare stocks declined late Thursday afternoon, with the NYSE Healthcare Index decreasing 0.9% a PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Earnings Call Insights: Maravai LifeSciences (MRVI) Q2 2026 MANAGEMENT VIEW * "We are very pleased with our second quarter performance, which builds on the strong momentum we established in the first quarter." (CEO & Director Bernd Brust)…
Maravai LifeSciences Holdings Inc. (NASDAQ:MRVI) is one of the top penny stocks to buy in investors’ stock portfolio. On May 7, Maravai LifeSciences Holdings Inc. (NASDAQ:MRVI) affirmed a strong start to the year, driven by strong demand i…
Image source: The Motley Fool. DATE May 7, 2026 CALL PARTICIPANTS Chief Executive Officer — Bernd BrustChief Financial Officer — Rajesh AsarpotaChief Scientific Officer — Chanfeng ZhaoInvestor Relations — Debra Hart Need a quote from a Mot…
Image source: The Motley Fool. DATE May 7, 2026 CALL PARTICIPANTS Chief Executive Officer — Bernd Brust Chief Financial Officer — Rajesh Asarpota Chief Scientific Officer — Chanfeng Zhao Investor Relations — Debra Hart Need a quote from a…
Maravai LifeSciences logo Key Points Interested in Maravai LifeSciences Holdings, Inc.? Here are five stocks we like better. Strong Q1 results: Maravai reported $65.8 million in revenue (up 41% YoY), adjusted gross margin of 65.3%, adjuste…
Baxter International (BAX) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.55 per share a year ago. These figures are adjusted for non-recurring…
As February 2026 begins, U.S. stock markets have shown resilience with major indices like the Dow Jones and S&P 500 ending sharply higher, buoyed by positive economic indicators such as an unexpected expansion in factory activity. In this…
Tejara Capital Ltd disclosed a buy of 69,700 Teleflex(NYSE:TFX) shares in a February 5 SEC filing, with an estimated transaction value of $8.45 million based on quarterly average pricing. What happened According to a Securities and Exchang…
On February 5, Tejara Capital reported selling out of Arcutis Biotherapeutics(NASDAQ:ARQT), unloading 520,503 shares in an estimated $9.81 million trade based on quarterly average pricing. What happened According to a U.S. Securities and E…
Key Points Tejara Capital sold 520,503 shares of Arcutis Biotherapeutics in the fourth quarter. The quarter-end position value decreased by $9.81 million, reflecting the full exit and price changes. The move marked an exit, with the positi…
As the U.S. market experiences a surge, with major indexes like the Dow Jones Industrial Average reaching all-time highs following geopolitical developments, small-cap stocks are drawing attention amidst this buoyant economic backdrop. In…
(RTTNews) - Aptamer Group (P0J.F, APTA.L) and Alphazyme, a Maravai LifeSciences (MRVI) company, have entered into a licensing agreement for a developed Optimer for use in hot-start PCR applications. Aptamer grants Alphazyme a non-exclusive…
(RTTNews) - Biotech stocks showed sharp moves in extended trading, with several names rebounding after steep regular-session losses. Fresh clinical data, FDA designations, and financing announcements drove momentum across the sector, highl…
Maravai LifeSciences Holdings, Inc. (MRVI) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.02 per share a year ago. These figures are adjusted for non-…
* Maravai LifeSciences Holdings press release [https://seekingalpha.com/pr/20297746-maravai-lifesciences-reports-third-quarter-2025-financial-results] (MRVI [https://seekingalpha.com/symbol/MRVI]): Q3 Non-GAAP EPS of -$0.08 in-line. * Reve…
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Maravai (MRVI) To Contact Him Directly To Discuss Their Options If you purchased or acquired common stock in Maravai LifeSciences bet…
As the U.S. stock market sees fluctuations with major indices like the S&P 500 and Nasdaq hitting new records, investors are increasingly exploring diverse investment opportunities. Penny stocks, despite their old-fashioned name, remain a…
In trading on Tuesday, the Simplify Macro Strategy ETF is outperforming other ETFs, up about 7.1% on the day. Components of that ETF showing particular strength include shares of Maravai Lifesciences Holdings, up about 7.2% and shares of A…
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Maravai (MRVI) To Contact Him Directly To Discuss Their Options If you purchased or acquired common stock in Maravai LifeSciences bet…
[M&A - concept waiting for mergers and acquisitions.3D rendering on yellow background.] Deal activity will rise by 15% in 2026, according to Goldman Sachs. Strategist David Kostin says M&A activity will increase next year "alongside accele…
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Maravai (MRVI) To Contact Him Directly To Discuss Their Options If you purchased or acquired common stock in Maravai LifeSciences bet…
As the S&P 500 and Nasdaq Composite reach record highs, driven by optimism around potential interest rate cuts, investors are increasingly exploring diverse avenues for growth. Penny stocks, a term that traditionally refers to low-priced s…
Earnings Call Insights: Maravai LifeSciences Holdings, Inc. (MRVI) Q2 2025 MANAGEMENT VIEW * CEO Bernd Brust opened his first earnings call by noting, "I came into this role with a clear understanding that realizing Maravai's full potentia…
Announced organizational restructuring and operating cost reduction initiatives targeting more than $50 million in annualized cost savings Quarterly base business revenue, which excludes revenue from high-volume CleanCap® for commercialize…
Earnings season continues, with several notable companies set to release their financial results for the upcoming trading day. Leading the pack are mining giant Barrick Gold, biopharmaceutical company Roivant Sciences (NASDAQ:ROIV), and he…
Exploring the Strategic Moves of First Pacific Advisors (Trades, Portfolio) in Q2 2025 Warning! GuruFocus has detected 5 Warning Sign with META. First Pacific Advisors (Trades, Portfolio) recently submitted its 13F filing for the second qu…
SAN DIEGO, July 28, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its second quarter 2025 fina…
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Maravai (MRVI) To Contact Him Directly To Discuss Their Options If you purchased or acquired common stock in Maravai LifeSciences bet…
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) announced Friday that its Audit Committee has approved the appointment of Deloitte & Touche LLP as the company’s independent registered public accounting firm for the fiscal year ending Dec…
SAN DIEGO, July 18, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, is investigating potential violations of federal and state securities laws by certain officers and directors of Quantum Computing Inc. (NASDAQ: QUBT), AppLovin Corporation…
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Maravai (MRVI) To Contact Him Directly To Discuss Their Options If you purchased or acquired common stock in Maravai LifeSciences bet…
NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) on behalf of long-te…
The market has stayed flat over the past week, but it is up 13% over the past year, with earnings forecasted to grow by 15% annually. In such a setting, investors often look for stocks that combine value and growth potential, particularly…